Citigroup’s Cardio Diagnostics CDIO Stock Holding History

Citigroup’s Portfolio CDIO Stock Details CDIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1	Closed	-$2	–	5784
2026 Q1	$2	Sell	1 -25	-96%	-$65	﹤0.01%	5824
2025 Q4	$70	Buy	+26	New	+$95	﹤0.01%	5686
2025 Q1	–	Sell	-30	Closed	-$825	–	5624
2024 Q4	$825	Buy	+30	New	+$416	﹤0.01%	5608

Other funds holding CDIO

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Citigroup's CDIO Position: Q2 2026 in Review

Citigroup sold out of Cardio Diagnostics (CDIO) in Q2 2026, closing a stake of 1 share — an estimated $2 sold.

Citigroup first reported a position in CDIO in Q4 2024 and held it in 3 quarters. The position peaked at $825 in Q4 2024. 17 funds tracked by Wall St. Rank hold CDIO as of Q2 2026.

Citigroup reported no remaining Cardio Diagnostics position as of Q2 2026 after selling out during the quarter.
Citigroup sold 1 Cardio Diagnostics share in Q2 2026, an estimated $2.
Citigroup first reported a position in Cardio Diagnostics in Q4 2024 and held it in 3 quarters.
Citigroup's Cardio Diagnostics position peaked at $825 in Q4 2024.
17 funds tracked by Wall St. Rank held Cardio Diagnostics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.